Isabel Cruz

1.1k total citations
8 papers, 8 citations indexed

About

Isabel Cruz is a scholar working on Epidemiology, Hematology and Molecular Biology. According to data from OpenAlex, Isabel Cruz has authored 8 papers receiving a total of 8 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Epidemiology, 3 papers in Hematology and 2 papers in Molecular Biology. Recurrent topics in Isabel Cruz's work include Multiple Myeloma Research and Treatments (3 papers), Protein Degradation and Inhibitors (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Isabel Cruz is often cited by papers focused on Multiple Myeloma Research and Treatments (3 papers), Protein Degradation and Inhibitors (2 papers) and Chronic Myeloid Leukemia Treatments (2 papers). Isabel Cruz collaborates with scholars based in United Kingdom, Portugal and United States. Isabel Cruz's co-authors include Lucía Muñoz-Narbona, Francisco Martín‐Herrero, João Azevedo, David Hughes, Benjamin Li, Rahul Banerjee, Chi Heon Kim, Francisco Carmona-Torre, José Ramón Yuste and Meera Mohan and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cardiovascular Research and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Isabel Cruz

3 papers receiving 8 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Isabel Cruz United Kingdom	2	5	4	2	2	1	8	8
Martin Drinković Croatia	2	4 0.8×	3 0.8×	3 1.5×			5	7
Eleonora Ciccioli Italy	1	4 0.8×	6 1.5×				2	6
J. Park South Korea	2	3 0.6×	4 1.0×				2	4
C. L. Luo China	2	3 0.6×	5 1.3×				14	7
Sathish Muthu India	2	2 0.4×	3 0.8×				3	5
R De Vincenti Italy	2	3 0.6×	3 0.8×	1 0.5×			3	5
O AlAamer Saudi Arabia	2	5 1.0×	7 1.8×				3	8
PK Chan Malaysia	2	2 0.4×	4 1.0×				4	5
Masaru Yamakawa Japan	3	3 0.6×	3 0.8×				4	13
Carolyn Hargreaves United Kingdom	2	2 0.4×	2 0.5×				2	9

Countries citing papers authored by Isabel Cruz

Since Specialization

Citations

This map shows the geographic impact of Isabel Cruz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabel Cruz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabel Cruz more than expected).

Fields of papers citing papers by Isabel Cruz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabel Cruz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabel Cruz. The network helps show where Isabel Cruz may publish in the future.

Co-authorship network of co-authors of Isabel Cruz

This figure shows the co-authorship network connecting the top 25 collaborators of Isabel Cruz. A scholar is included among the top collaborators of Isabel Cruz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabel Cruz. Isabel Cruz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

LeBlanc, Thomas W., et al.. (2025). Elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research. 14(5). e240236–e240236. 1 indexed citations

2.

Lópes, Renato D., et al.. (2025). Dilated cardiomyopathy following mesalazine treatment. SHILAP Revista de lepidopterología. 8(2). 100500–100500.

3.

LeBlanc, Thomas W., et al.. (2025). Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results. Journal of Blood Medicine. Volume 16. 233–239. 2 indexed citations

4.

Banerjee, Rahul, Meera Mohan, Nileesa Gautam, et al.. (2025). EE85 Real-World Healthcare Resource Utilization and Costs Associated with Elranatamab Initiation in Multiple Myeloma: the ALTITUDE-1 Study. Value in Health. 28(6). S77–S78.

5.

Cruz, Isabel, et al.. (2024). Rheumatoid arthritis and pericardial effusion – a unique major manifestation. European Journal of Case Reports in Internal Medicine. 11(2). 4159–4159.

6.

Bilbao, I., et al.. (2024). Use of echinocandins combined with clindamycin in Pneumocystis pneumonia: a case series of 14 patients. Journal of Antimicrobial Chemotherapy. 80(1). 102–105.

7.

Cruz, Isabel, et al.. (2022). Poster No. 040 Traversing boundaries inside the heart. Cardiovascular Research. 118(Supplement_2).

8.

Martín‐Herrero, Francisco, Isabel Cruz, & Lucía Muñoz-Narbona. (2006). Hepatic hydatid cyst rupturing into pericardial cavity. Heart. 92(10). 1536–1536. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact